Spark Investment Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Spark Investment Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-18,500	Closed	-$3.78M	–	558
2019 Q4	$3.78M	Buy	+18,500	New	+$3.37M	0.44%	61
2019 Q3	–	Sell	-13,700	Closed	-$1.29M	–	540
2019 Q2	$1.29M	Hold	13,700	–	–	0.09%	262
2019 Q1	$1.17M	Buy	13,700 +4,100	+43%	+$340K	0.05%	322
2018 Q4	$538K	Buy	+9,600	New	+$586K	0.04%	386
2016 Q3	–	Sell	-34,300	Closed	-$677K	–	906
2016 Q2	$677K	Buy	+34,300	New	+$667K	0.06%	395

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Spark Investment Management's RETA Position: Q1 2020 in Review

Spark Investment Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2020, closing a stake of 18,500 shares — an estimated $3.78M sold.

Spark Investment Management first reported a position in RETA in Q2 2016 and held it in 5 quarters. The position peaked at $3.78M in Q4 2019. 214 funds tracked by Wall St. Rank hold RETA as of Q1 2020.

Spark Investment Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2020 after selling out during the quarter.
Spark Investment Management sold 18,500 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2020, an estimated $3.78M.
Spark Investment Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 5 quarters.
Spark Investment Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3.78M in Q4 2019.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2020.

Based on Spark Investment Management's 13F filing for Q1 2020, filed 12 May 2020.